Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

Resistance against Epstein-Barr virus from experimental monoclonal antibodies

When tested in a lab setting using human cells, a panel of experimental monoclonal antibodies (mAbs) that target various Epstein-Barr virus (EBV) sites prevented infection.

1 Nov 2022

Simple blood test helps identify patients developing neurotoxic side effects

The treatment of various tumors has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. To target and combat specific forms of leukemia and lymphoma, the treatment employs genetically engineered T cells.

8 Sep 2022

Researchers find immune-effective ways to destroy cancer cells

Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.

26 Jul 2022

Scientists discover proteins that may improve CAR-T cell therapy for solid tumor model

The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.

27 Jun 2022

Researchers discover a new interferon-gamma receptor signaling pathway

The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).

10 Jun 2022

Study shows new potential target for CAR T cells to inhibit solid tumors

CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.

10 May 2022

Gene expression signatures in lymph node cells play an active role in lymphoma development

Researchers from the University of Tsukuba identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of lymphomas.

3 May 2022

CAR-T cell treatment via implantable biotechnology more effective in combating cancer

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.

25 Mar 2022

Study uncovers genomic drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma

Cutaneous T-cell lymphoma (CTCL) is an incurable, rare cancer of skin-homing T cells that is highly disfiguring and lethal at advanced stages.

2 Mar 2022

Study decodes the heterogeneity of tumor-infiltrating immune cell composition in diffuse large B-cell lymphoma

In Finland, about 700 people are identified with diffuse large B-cell lymphoma (DLBCL) every year.

24 Feb 2022

Leukemia-on-a-chip; The Future of Preventing Therapy Resistance?

We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.

From Society for Laboratory Automation and Screening (SLAS) 27 Jan 2022

CAR T cells produced in vivo using modified mRNA treat cardiac injury

A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.

10 Jan 2022

Researchers discover a crucial and exploitable vulnerability in diffuse large B cell lymphomas

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell's Ithaca campus.

4 Jan 2022

Researchers develop new CAR T cells that act as a "micropharmacy"

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers.

3 Jan 2022

Biochemical signals sent from cell to cell play a key role in deciding their fate

Scientists have found a way to prove that biochemical signals sent from cell to cell play an important role in determining how those cells develop.

24 Dec 2021

Researchers develop novel technique to monitor remote immune mechanisms

The human immune system works hard to maintain an individual’s health and protect against viruses, bacteria, parasites, fungi, and cancerous cells.

17 Dec 2021

Driving up the immune response at tumor site may help boost immunotherapy

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

15 Dec 2021

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

13 Dec 2021

Researchers identify a new approach to triggering differentiation in acute myeloid leukemia

In the late 1980s, scientists developed a revolutionary approach to treating acute myeloid leukemia (AML), a type of blood cancer. Called differentiation therapy, it amounted to a bona fide cure for many patients.

2 Dec 2021